Pharsight

Aloxi patents expiration

ALOXI's oppositions filed in EPO
ALOXI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066980 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US8729094 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US9457020 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US8518981 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US9439854 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US7947725 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US8598218 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US9457021 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US9125905 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US7960424 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US9173942 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US7947724 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US8598219 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(4 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(10 months from now)

Aloxi is owned by Helsinn Hlthcare.

Aloxi contains Palonosetron Hydrochloride.

Aloxi has a total of 26 drug patents out of which 0 drug patents have expired.

Aloxi was authorised for market use on 25 July, 2003.

Aloxi is available in injectable;intravenous dosage forms.

Aloxi can be used as prevention of chemotherapy-induced nausea and vomiting.

The generics of Aloxi are possible to be released after 30 July, 2024.

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2003

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage

ALOXI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic